12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ampligen rintatolimod regulatory update

FDA's Arthritis Advisory Committee will meet on Dec. 20 to discuss an NDA for Ampligen rintatolimod to treat chronic fatigue syndrome (CFS). The NDA has a Feb. 2,...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >